1. Home
  2. WAVE vs SKYE Comparison

WAVE vs SKYE Comparison

Compare WAVE & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eco Wave Power Global AB (publ)

WAVE

Eco Wave Power Global AB (publ)

N/A

Current Price

$6.13

Market Cap

43.3M

Sector

Utilities

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.06

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAVE
SKYE
Founded
2011
2012
Country
Israel
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.3M
44.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
WAVE
SKYE
Price
$6.13
$1.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$15.00
$14.75
AVG Volume (30 Days)
11.4K
599.9K
Earning Date
11-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$168,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$400.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.41
$0.68
52 Week High
$11.46
$5.75

Technical Indicators

Market Signals
Indicator
WAVE
SKYE
Relative Strength Index (RSI) 42.23 50.87
Support Level $5.77 $0.68
Resistance Level $6.30 $1.15
Average True Range (ATR) 0.32 0.11
MACD 0.05 0.04
Stochastic Oscillator 54.33 80.67

Price Performance

Historical Comparison
WAVE
SKYE

About WAVE Eco Wave Power Global AB (publ)

Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: